The Notice of Allowance for a new patent is a critical regulatory milestone that can significantly impact BioLineRx's ability to produce Motixafortide at scale, potentially leading to increased product availability and revenue. The long validity period until 2041 also provides a prolonged competitive advantage and intellectual property protection, which are crucial for the company's valuation and investor confidence.